[Further characterization between oral bisphosphonate dosing interval and patient preference--patient preference for daily, weekly and monthly bisphosphonate, based on results of 3,052 outpatients questionnaires].

This single center questionnaire survey began in 15 February 2013 and ended in 31 May 2013 at our clinic. Patients were received the questionnaire to measure preference about bisphosphonate preparations (BPs). The questionnaire consisted of the following two questions: [which do you prefer once-daily, once-weekly or once-monthly bisphosphonate? why do you prefer any one?]. We studied 3,052 outpatients (822 male and 2,230 female) aged 63.7 +/- 18.0 years, had had various orthopedic diseases, including osteoporosis. Thirteen hundred and thirty four patients (43.7%) preferred once-weekly BPs. Once-monthly BPs and once-daily BPs were ranked second and third, 926 patients (30.3%) and 750 patients (24.6%), respectively. The dominant reasons for preferring once-weekly BPs, once-monthly BPs, and once-daily BPs, were "once-daily dosing schedule is troublesome, but, once-monthly dosing schedule tends to forget", "once-monthly dosing schedule is more convenient", and "it is hard to forget dosing by once-daily dosing schedule", respectively. Of 93 patients had already taken once-daily BPs, 62 patients (66.7%) preferred once-daily BPs. Of 672 patients had already taken once-weekly BPs, 419 patients (62.4%) preferred once-weekly BPs. Of 48 patients had already taken once-monthly BPs, 40 patients (83.3%) preferred once-monthly BPs. Patients tended to prefer BPs that were already administered. Three hundred and five patients were randomly assigned to switch from current osteoporosis medicine to once-monthly risedronate for two months, and these patients were received the questionnaire before and after the treatment period. The rate of preferring once-monthly BPs significantly increased from 39.0% to 81.0%, after taking once-monthly risedronate for two months. Therefore, these results revealed that patient preference for oral bisphosphonate dosing interval was varied. It was concluded that risedronate was useful for various patients, because it had once-daily, once-weekly, and once-monthly preparations.

RCT Entities:   Population Interventions Outcomes